Three things to know:
1. Bioventus’ Durolane and Gelsyn-3 treatments for knee osteoarthritis pain will be made available to UnitedHealth commercial plan members starting Oct. 1.
2. Durolane is a single-injection and Gelsyn-3 is a three-injection hyaluronic acid-based joint fluid treatment.
3. Bioventus plans to expand Durolane into Australia and New Zealand and is launching Durolane SJ — another HA-based product — in both countries later this year.
More articles on devices:
‘A dream come true’: Dr. Jorge Chahla strives for success at Rush
New York hospital invests $2M in imaging system for spine, brain — 4 things to know
What Stryker’s spine division stands to gain from 5 acquisitions
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
